Docstoc

VetDC Pitch Deck

Document Sample
VetDC Pitch Deck Powered By Docstoc
					                   VETDC, INC.
              Innovative, underutilized human
            biotechnologies for superior cancer
             treatments in companion animals.


   Steven Roy - CEO
steven.roy@vet-dc.com
     303-859-2072
 http://www.vetdc.com
Robust market for pet health
• Americans spending $13B annually
• 33% willing to pay $3K or more for pet illnesses
• Pet insurance industry gaining momentum
• Cancer is the next big opportunity
      – Leading killer of adult pets today
      – Few FDA-approved drugs, unmet need for better treatments
      – No other company is dedicated to this space
www.vetdc.com               VETDC PROPRIETARY                2
  We develop drugs that have
  demonstrated success in animals
                          Human Development
    Research        Preclinical     Phase I         Phase II       Phase III   Market



       Lab          Animals                                    Humans




                Veterinary Development                                   Faster to
     Safety &            Pilot         Pivotal                          market with
                                                         Market
    Tolerability         Efficacy      Study                             less risk
www.vetdc.com                        VETDC PROPRIETARY                                  3
 Our unique relationship gives us
 a huge advantage
        Access to CSU’s world-
         class Veterinary and
        Animal Cancer Centers


     Leading             Clinical            Pipeline of
   Researchers      Trial Capabilities      Opportunities
www.vetdc.com           VETDC PROPRIETARY                   4
   Our first drug: VDC-1101 is a
   powerful solution
     Pre-dose               Post-dose
                                                   • Exclusive license from Gilead
                                                   • Targeted agent
                                                        − Kills cancerous lymph cells

                                                   • Lymphoma data in 62 pet dogs
                                                        − Nearly 80% response rate
                                                        − Well tolerated

                                                   • Superior overall profile vs.
                                                     available alternatives
Vail D et al: Clin Cancer Res 15(10): 3503, 2009

    www.vetdc.com                             VETDC PROPRIETARY                         5
We have a proven team
   • Steven Roy, MBA – President & CEO
         – Former Director, Amgen Licensing; Aranesp® Oncology Launch

   • Ann Donoghue, MS, DVM – Sr. Dir. Regulatory
         – 4 NADAs, 3 USDA licenses and 2 EPA registrations

   • Douglas Johnson, PhD – Head of Manufacturing
         – Former Mfg. VP; 20 yrs CMC experience - 4 NDAs and 10 INDs

   • Douglas Thamm, VMD – Clinical Development
         – Dip ACVIM, Assoc. Professor Oncology, 24 clinical trials

   • Terry Opgenorth, PhD – Chief Scientific Officer
         – Former VP Drug Discovery, Abbott Human Health; 10 drugs in clinic
www.vetdc.com                        VETDC PROPRIETARY                         6
Clear milestones to success
          2012                     2013                           2014

        FDA-CVM
        Consensus
                         MUMS Designation
                          Data Submission                                 Fast-to-
                                                     FDA                  Market
                 Manufacturing Development           Submission
                                                          Approval


                             1st Line Canine Studies
                                                                           Label
                                                                         Expansion
                                 Feline Safety & Efficacy

www.vetdc.com                    VETDC PROPRIETARY                            7
 Can launch with a focused campaign
$60,000,000
                                                                  Tier 2
                                                           Specialty Clinics                                    Patients
$50,000,000                                                                                                      52,875
                                                              (n=1,200)
                                                                                           Patients
$40,000,000                                                                                 36,617
                                     Tier 1
$30,000,000                    Vet Oncologists
                                   (n=250)
                                                                         Patients
$20,000,000                                                               15,000


$10,000,000                                            Patients
                                                        4,671

         $-
                   2012               2013              2014              2015              2016                 2017

   Note: $200/unit wholesale in 2012 and increasing 3% per year, 5 units/patient for Dogs; $100/unit for Cats
  www.vetdc.com                                     VETDC PROPRIETARY
Aggressively pursuing a pipeline
• Four novel cancer targets
     – Three approached VetDC
     – All have preclinical packages
     – One at term sheet stage


      Potential in Osteosarcoma, Hemangiosarcoma,
    Lymphoma, Melanoma, Solid Tumors, Inflammation
www.vetdc.com            VETDC PROPRIETARY           9
 $5M propels VetDC to success
• $2 million to complete regulatory/mfg. filing
    – Convertible Preferred Stock
    – $500K of $2M goal committed
    – Value step-up on completion of filing activities

• Raise additional $2-3 million for go-to-market
  & pipeline development
    – A commercialization partnership could off-load costs
    – Big valuation step-up on approval
    – 4-5 year exit from a top-tier animal health company acquisition
www.vetdc.com                 VETDC PROPRIETARY                     10

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:75
posted:9/4/2012
language:English
pages:10
Description: VetDC Pitch Deck